Member Article

Pharmanovia Announces Rebrand of its Benelux Business to Pharmanovia Benelux

Drug life cycle management company, Pharmanovia, has announced today that it has completed the final phase of its acquisition of Lamepro, which has now been rebranded to Pharmanovia Benelux.

Founded in 1980, Lamepro has developed into an experienced and reliable partner for international pharmaceutical companies due to its dedication and expertise in marketing, sales, and distribution of pharmaceutical products. It was acquired in October 2020 by Pharmanovia.

Pharmanovia provides provide iconic, tried, and trusted medicines in the strategic therapeutic areas of Cardiovascular, Endocrinology, Neurology, and Oncology. The company’s purpose is to revitalise iconic medicines for the benefit of patients globally. Pharmanovia operates in 140+ markets with over 250 employees, growing through development, licensing, and acquisition. It owns some of the world’s most recognisable brands and operates a diverse portfolio of 20+ brands.

Dr. James Burt, Chief Executive Officer of Pharmanovia comments: “We are proud to officially welcome Pharmanovia Benelux into our group, and we are excited to see what the future brings as we grow together to reflect our new strategy to improve patient health globally. Our continuous growth and operational efficiency show that we are capable of adapting to these great developments.”

Just van Diemen, General Manager, Pharmanovia Benelux added, “Our rebrand doesn’t mark the completion of our mission, it marks the evolution! A more diversified portfolio can now be offered to our partners with the aim of improving patient experience. We are extremely proud to be part of such a dynamic company.”

The Pharmanovia brand identity is rolling out across all of Lamepro’s touchpoints and platforms – internal and external, physical, and digital – from today.

This was posted in Bdaily's Members' News section by Nathan Stennett .